Understand the study
Retatrutide: What Does the 24.2% Weight-Loss Result Mean?
Read the 338-person trial without confusing an average result with a promise.
Why did researchers study it?
Retatrutide acts at three receptors called GIP, GLP-1 and glucagon receptors. A receptor is a cell’s receiving point for a signal. Having three targets explains the research interest, but the number of targets cannot tell us the size of the effect. That requires an experiment.
How was the comparison made?
The trial randomly assigned adults with obesity, or overweight plus a weight-related condition, to retatrutide regimens or placebo. Placebo supplies a comparison without the active study compound. The study’s main weight assessment was at week 24; participants were followed for 48 weeks. The later result should therefore be described as the week-48 result.
- 01Study question
- 02338 adults
- 0348-week comparison
What happened by week 48?
The reported average weight changes were −8.7%, −17.1%, −22.8% and −24.2% in the 1, 4, 8 and 12 mg study groups, compared with −2.1% for placebo. These are the trial’s adjusted group estimates. The amounts identify experimental groups, not a guide to using research material. [1]
Does 24.2% mean everyone lost that much?
No. An average summarizes a group and hides differences between individuals. As arithmetic only, 24.2% of a hypothetical starting weight of 100 kg is 24.2 kg. This explains the percentage; it does not predict anyone’s result. Also compare changes at the same time point: a 24-week value and a 48-week value answer different questions.
What else needs attention?
Digestive adverse events were the most common, and the paper also reported heart-rate changes. A benefit-only summary leaves out important information. This was a phase-2 study that explored different regimens. It was not a direct retatrutide-versus-tirzepatide comparison and cannot settle that ranking. [1]
How does this connect with research material?
The study helps define a research question about retatrutide. It does not test an NHD catalog batch. For a laboratory project, the product link below is the next place to confirm the named material, available variants and required records. A clinical trial preparation and a research-use material are separate products.
Explore the research topic
Related research products
Retatrutide
Weight and metabolism research
View product
Tirzepatide
Weight and metabolism research
View product
Survodutide
Weight and metabolism research
View productImages illustrate the catalog. Related products are further reading, not claims of equal effects or interchangeability.
Original research and reading notes
Study amounts and preparations identify experimental conditions, not recommended use. AI-assisted research explanation; sources checked 11 October 2026. NHD catalog materials are for research, development and manufacturing, not human or veterinary use.